Search results for "genetic disorder"

showing 9 items of 39 documents

Xeroderma Pigmentosum – A case report with oral implications

2012

Xeroderma Pigmentosum is a rare autosomal recessive genetic disorder characterized by defective DNA repair leading to clinical and cellular hypersensitivity to ultraviolet radiation and carcinogenic agents. Important clinical features are: intense cutaneous photosensitivity, xerosis, poikiloderma, actinic keratosis, acute burning under minimal sun exposure, erythemas, hyperpigmented lentiginous macules, and malignant lesions in sun-exposed areas, including basocellular carcinoma, squamous cell carcinoma, and melanoma. There is a great involvement of many parts of the body, especially head and neck. The oral manifestations are mainly related to the occurrence of malignant tumors in the lips,…

Pathologymedicine.medical_specialtyXeroderma pigmentosumScarsPoikilodermaOdontologíaCase ReportTongueCarcinomaMedicineskin and connective tissue diseasesGeneral DentistryOral Medicine and Pathologyintegumentary systembusiness.industryMelanomaActinic keratosisGenetic disordermedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludstomatognathic diseasesmedicine.anatomical_structureUNESCO::CIENCIAS MÉDICASDERMATOPATIASmedicine.symptombusinessJournal of Clinical and Experimental Dentistry
researchProduct

New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia.

2021

: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder. The most common cause is a mutation in both alleles of the gene encoding for the low-density lipoprotein (LDL) receptor, although other causative mutations have been identified. Complications of atherosclerotic cardiovascular disease are common in these patients; therefore, reducing the elevated LDL-cholesterol burden is critical in their management. Conventionally, this is achieved by patients initiating lipid-lowering therapy, but this can present challenges in clinical practice. Fortunately, novel therapeutic strategies have enabled promising innovations in HoFH treatment. This review highlights recent and ongo…

Settore MED/09 - Medicina InternaGenetic enhancementHomozygous familial hypercholesterolemiaFamilial hypercholesterolemiaInclisiranBioinformaticsmedicine.disease_causeBenzimidazolePCSK9Hyperlipoproteinemia Type IIchemistry.chemical_compoundGene therapyAnticholesteremic AgentmedicineAngiopoietin-like 3HumansLow-density lipoprotein cholesterolAlleleAngiopoietin-like 3; Gene therapy; Gene-editing; Homozygous familial hypercholesterolemia; Inclisiran; Lomitapide; Low-density lipoprotein cholesterol; PCSK9MutationGene-editingAtherosclerotic cardiovascular diseasebusiness.industryPCSK9Anticholesteremic AgentsHomozygoteGenetic disorderGeneral MedicineCholesterol LDLmedicine.diseaseLomitapideLomitapidechemistrylipids (amino acids peptides and proteins)BenzimidazolesCardiology and Cardiovascular MedicinebusinessHumanHeart failure clinics
researchProduct

The new world of human genetic technologies: The policy environment and impacts of genetic screening tests

1995

Today it is possible to screen for mutated DNA sequences which do not induce any diseases but predispose to develop diseases under certain environmental condition. These latter disorders are called “multifactorial” since they result from the interplay of genetic and environmental factors. Among multifactorial disorders there are job-related diseases whose genetic component can be identified by genetic screening tests. The use of these tests to predict occupational disorders, to cut down on them, and to save costs—in particular for absenteeism, health care, and lawsuits—is of interest to employers and insurers. As for employees, it could entail an extremely deep invasion of privacy, economic…

business.industryGenetic counselingGenetic disorderPrivacy laws of the United StatesDiseasemedicine.diseaseHuman-Computer InteractionPhilosophyRisk analysis (engineering)Artificial IntelligenceHealth caremedicineAbsenteeismGenetic predispositionBusinessEconomic problemAI & Society
researchProduct

Human pasteurized C1-inhibitor concentrate for the treatment of hereditary angioedema due to C1-inhibitor deficiency.

2011

Hereditary angioedema is a relatively rare genetic disorder affecting between one in 10,000 and one in 50,000 individuals worldwide. The most common clinical symptoms observed are relapsing swelling of the skin and abdominal pain attacks. However, more serious and potentially fatal laryngeal attacks can also occur. Hereditary angioedema is most frequently caused by a deficiency of C1-inhibitor. Replacement therapy with Berinert, an intravenous pasteurized C1-inhibitor concentrate derived from human plasma, is a recommended treatment for rapid resolution of acute attacks of hereditary angioedema due to C1-inhibitor deficiency. Prophylactic therapy with C1-inhibitor is also available. Future …

medicine.medical_specialtyAbdominal painC1 inhibitor deficiencyImmunologyComplement C1 Inactivator ProteinsC1-inhibitormedicineImmunology and AllergyHumansInfusions IntravenousAngioedemabiologybusiness.industryGenetic disorderAngioedemas Hereditaryfood and beveragesmedicine.diseaseDermatologyAbdominal PainHuman plasmaImmunologyHereditary angioedemabiology.proteinBerinert PPasteurizationmedicine.symptombusinessComplement C1 Inhibitor ProteinExpert review of clinical immunology
researchProduct

Effects of l-Carnitine in Patients with Autism Spectrum Disorders: Review of Clinical Studies

2019

Carnitine is an amino acid derivative, which plays several important roles in human physiology, in the central nervous system, and for mitochondrial metabolism, in particular. Altered carnitine metabolic routes have been associated with a subgroup of patients with autism spectrum disorders (ASD) and could add to the pathophysiology associated with these disorders. We review the current evidence about the clinical effects of carnitine administration in ASD in both non-syndromic forms and ASD associated with genetic disorders. Two randomized clinical trials and one open-label prospective trial suggest that carnitine administration could be useful for treating symptoms in non-syndromic ASD. Th…

medicine.medical_specialtyAutism Spectrum DisorderCentral nervous systemPharmaceutical ScienceReviewComorbidityAnalytical Chemistrylaw.inventionlcsh:QD241-44103 medical and health sciences0302 clinical medicineNeurodevelopmental disorderlcsh:Organic chemistryRandomized controlled triallawCarnitineInternal medicinemental disordersDrug DiscoveryIntellectual disabilitymedicineHumansgenetic disordersGenetic Predisposition to DiseaseCarnitinePhysical and Theoretical ChemistryRandomized Controlled Trials as Topic030304 developmental biology0303 health sciencesDose-Response Relationship Drugbusiness.industryOrganic Chemistryvitaminmedicine.diseaseneurodevelopmental disorderPathophysiologyClinical trialTreatment Outcomemedicine.anatomical_structureChemistry (miscellaneous)Molecular MedicineAutismnutritional supplementationbusinessmetabolism030217 neurology & neurosurgerymedicine.drugMolecules
researchProduct

Hereditary angioedema: an update on causes, manifestations and treatment.

2019

Hereditary angioedema is a rare genetic disorder caused by deficiency of C1 esterase inhibitor (C1-INH) and characterized by recurrent episodes of severe swelling that affect the limbs, face, intestinal tract and airway. Since laryngeal oedema can be life-threatening as a result of asphyxiation, correct diagnosis and management of hereditary angioedema is vital. Hereditary angioedema attacks are mediated by bradykinin, the production of which is regulated by C1-INH. Hereditary angioedema therapy relies on treatment of acute attacks, and short- and long-term prophylaxis. Acute treatment options include C1-INH concentrate, icatibant and ecallantide. Self-administration of treatment is recomm…

medicine.medical_specialtyBradykinin03 medical and health sciences0302 clinical medicineimmune system diseasesmedicineHumanscardiovascular diseases030212 general & internal medicineskin and connective tissue diseasesHereditary Angioedema Types I and IIbusiness.industryGenetic disorderfood and beveragesGeneral Medicinemedicine.diseaseDermatologyC1 esterase030228 respiratory systemHereditary angioedemaFactor XIIDisease ProgressionQuality of LifeKallikreinsbusinessPeptidesComplement C1 Inhibitor ProteinBritish journal of hospital medicine (London, England : 2005)
researchProduct

How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks fo…

2020

Familial hypercholesterolemia (FH) is a common genetic disorder of lipid metabolism, still underdiagnosed and undertreated in the general population. Pathology registers could play a crucial role in the creation of a comprehensive and integrated global approach to cover all aspects of this disease. Systematic data collection of patients affected by FH has increased dramatically worldwide in the past few years. Moreover, results from registers already established for the longest time showed their potentialities in the implementation of the knowledge of FH, comparing country-specific approaches and providing real-world data about identification, management and treatment of FH individuals in t…

medicine.medical_specialtyGenotypeFamilial hypercholesterolemiaPopulationFamilial hypercholesterolemiaDisease030204 cardiovascular system & hematologyHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineGenetic dyslipidaemiasFamilial hypercholesterolemia; Genetic dyslipidaemias; Pathology registersInternal MedicineHumansMedicineGenetic Predisposition to DiseaseRegistries030212 general & internal medicineeducationIntensive care medicineHypolipidemic Agentseducation.field_of_studybusiness.industryGenetic disorderDiagnostic algorithmsGeneral MedicinePathology registersmedicine.diseaseClinical PracticePhenotypeItalyCardiovascular DiseasesHeart Disease Risk FactorsDisease riskIdentification (biology)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessAlgorithmsAtherosclerosis Supplements
researchProduct

Pasteurized C1 inhibitor concentrate in hereditary angioedema: pharmacology, safety, efficacy and future directions

2010

Hereditary angioedema (HAE) is a relatively rare genetic disorder that is most commonly caused by a deficiency of C1 inhibitor. It is estimated that HAE affects at least one in 10,000 to one in 50,000 of the worldwide population, with relapsing swelling of the skin and abdominal pain attacks being the most common clinical symptoms. Most seriously, laryngeal edema associated with HAE may lead to death. Replacement therapy with intravenous pasteurized C1 inhibitor concentrate is the recommended treatment for acute attacks of HAE, resulting in a rapid resolution of symptoms. Pasteurized C1 inhibitor concentrates can also be used for prophylaxis of HAE, and are currently also being assessed for…

medicine.medical_specialtyeducation.field_of_studyAbdominal painAngioedemabiologybusiness.industryImmunologyPopulationGenetic disorderLaryngeal Edemamedicine.diseaseDermatologySurgeryC1-inhibitorHereditary angioedemamedicinebiology.proteinImmunology and Allergymedicine.symptomeducationbusinessDisease burdenExpert Review of Clinical Immunology
researchProduct

Risk-Reducing Gynecological Surgery in Lynch Syndrome: Results of an International Survey from the Prospective Lynch Syndrome Database.

2020

Purpose: To survey risk-reducing hysterectomy and bilateral salpingo-oophorectomy (BSO) practice and advice regarding hormone replacement therapy (HRT) in women with Lynch syndrome. Methods: We conducted a survey in 31 contributing centers from the Prospective Lynch Syndrome Database (PLSD), which incorporates 18 countries worldwide. The survey covered local policies for risk-reducing hysterectomy and BSO in Lynch syndrome, the timing when these measures are offered, the involvement of stakeholders and advice regarding HRT. Results: Risk-reducing hysterectomy and BSO are offered to path_MLH1 and path_MSH2 carriers in 20/21 (95%) contributing centers, to path_MSH6 carriers in 19/21 (91%) and…

medicine.medical_treatmentCàncer d'ovarilcsh:Medicinecomputer.software_genreleikkaushoitoCOLORECTAL-CANCER0302 clinical medicineHormone replacement therapy (female-to-male)munasarjasyöpäMalalties hereditàriesGynecological surgery030219 obstetrics & reproductive medicineManchester Cancer Research CentreDatabaseBrief ReportGeneral MedicineLynch syndrome3. Good healthESTROGENkohdunrungon syöpägynekologiset syövätovarian cancer030220 oncology & carcinogenesisendometrial cancerhormonihoitosyöpätauditHEALTHGenetic disordersGenetic counseling3122 Cancersehkäisevä lääketiede03 medical and health sciencesmedicinerisk-reducing surgeryMedical prescriptionLynchin oireyhtymäperinnölliset tauditHysterectomybusiness.industryResearchInstitutes_Networks_Beacons/mcrcHORMONE REPLACEMENT THERAPYEndometrial cancerlcsh:RInternational survey3126 Surgery anesthesiology intensive care radiologymedicine.diseaseLynch syndromeCàncer d'endometririsk reducing surgerybusinesscomputer
researchProduct